What's breaking now, across thousands of outlets.
One analyst views Roivant’s pulmonary hypertension drug as a future $10 billion-plus seller. Elsewhere, AstraZeneca overcame a negative advisory committee vote and Pharvaris claimed success in a key study.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
This is one outlet's version. Read the fullest account.
Researchers from Cambridge and Basel have developed small molecules that could make cancer immunotherapies more effective.
IHE's concentrated pharma focus delivered 50% gains versus IYH's 27.4%, though the broader healthcare fund offers more diversification and $3.9B in assets.
Astra Health's five founding members, who serve more than half a million patients annually, hope to improve quality and trim costs at scale while maintaining their independence.
The Trump administration is cracking down further on durable medical equipment suppliers as part of its broader push to root out fraud.
Former President Joe Biden has shared an update on his battle with prostate cancer, saying radiation treatment has worked.
